1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
1. A method for treating, controlling, or ameliorating a central nervous system disorder in a mammal, the central nervous system disorder being epilepsy or a convulsive disorder selected from the group of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms, and epilepsy partialis continua, wherein the method comprises administering to the mammal in need thereof a compound having the formula (I)
or a stereochemically isomeric form, a pharmaceutically acceptable salt, or a solvate thereof,
wherein
R 1 is C 1-6 alkyl; or C 1-3 alkyl substituted with C 3-7 cycloalkyl, phenyl, or phenyl substituted with halo, trifluoromethyl, or trifluoromethoxy;
R 2 is halo, trifluoromethyl, C 1-3 alkyl, or cyclopropyl;
R 3 is hydrogen, fluoro, hydroxyl, hydroxyC 1-3 alkyl, hydroxy, C 1-3 alkyloxy, fluoroC 1-3 alkyl, fluoroC 1-3 alkyloxy, or cyano; and
Ar is unsubstituted phenyl.
2. The method of claim 1 wherein
R 1 is 1-butyl, 2-methyl-1-propyl, 3-methyl-1-butyl, (cyclopropyl)methyl, or 2-(cyclopropyl)-1-ethyl; and
R 3 is hydrogen, fluoro or cyano.
3. The method of claim 1 wherein
R 1 is 1-butyl, 3-methyl-1-butyl, (cyclopropyl)methyl, or 2-(cyclopropyl)-1-ethyl; and
R 2 is chloro; R 3 is hydrogen or fluoro.
4. The method of claim 1 wherein said compound is:
3′-chloro-1′-cyclopropylmethyl-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4]bipyridinyl-2′-one;
1′-butyl-3′-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4]bipyridinyl-2′-one;
or a pharmaceutically acceptable salt or a solvate thereof.
5. The method of claim 1 , wherein the central nervous system disorder is epilepsy.
6. The method of claim 1 , further comprising administering an orthosteric agonist of mGluR2 in combination with the compound of formula (I).
7. The method of claim 1 , wherein the compound is:
8. The method of claim 1 , wherein the mammal is a human patient.
9. The method of claim 7 , wherein the mammal is a human patient.
10. The method of claim 8 wherein
R 1 is 1-butyl, 2-methyl-1-propyl, 3-methyl-1-butyl, (cyclopropyl)methyl, or 2-(cyclopropyl)-1-ethyl; and
R 3 is hydrogen, fluoro or cyano.
11. The method of claim 8 wherein
R 1 is 1-butyl, 3-methyl-1-butyl, (cyclopropyl)methyl, or 2-(cyclopropyl)-1-ethyl; and
R 2 is chloro; R 3 is hydrogen or fluoro.
12. The method of claim 8 wherein said compound is:
3′-chloro-1′-cyclopropylmethyl-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4]bipyridinyl-2′-one;
1′-butyl-3′-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4]bipyridinyl-2′-one;
or a pharmaceutically acceptable salt or a solvate thereof.
13. The method of claim 8 , further comprising administering an orthosteric agonist of mGluR2 in combination with the compound of formula (I).
14. The method of claim 9 , further comprising administering an orthosteric agonist of mGluR2 in combination with the compound of formula (I).